PMID- 33081494 OWN - NLM STAT- MEDLINE DCOM- 20210706 LR - 20210706 IS - 1758-1001 (Electronic) IS - 0004-5632 (Linking) VI - 58 IP - 2 DP - 2021 Mar TI - Vascular endothelial growth factor (VEGF)-A and VEGF-A(165)b are associated with time to remission of granulomatosis with polyangiitis in a nationwide Japanese prospective cohort study. PG - 86-94 LID - 10.1177/0004563220968371 [doi] AB - BACKGROUND: Effective prognostic markers are needed for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study evaluated the clinical associations of serum vascular endothelial growth factor-A (sVEGF-A) and sVEGF-A(165)b (an antiangiogenic isoform of VEGF-A) concentrations with time to remission of AAV in a nationwide Japanese prospective follow-up cohort. METHODS: We collected samples from patients with AAV who were enrolled in the nationwide Japanese cohort study (RemIT-JAV-RPGN). We measured sVEGF-A and sVEGF-A(165)b concentrations using enzyme-linked immunosorbent assays in 57 serum samples collected 6 months before and after initiation of AAV treatment. Patients were classified based on AAV disease subtypes: microscopic polyangiitis, granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis (EGPA). RESULTS: Results revealed significant reductions in sVEGF-A and sVEGF-A(165)b concentrations in patients with microscopic polyangiitis and EGPA, respectively. However, despite the comparable concentrations of sVEGF-A and sVEGF-A(165)b during the 6 months of treatment in granulomatosis with polyangiitis patients, correlation analysis revealed that the differences in log(2)-transformed concentrations of sVEGF-A and sVEGF-A(165)b were inversely correlated with time to remission in granulomatosis with polyangiitis patients. CONCLUSION: These results suggest that sVEGF-A and -A(165)b can serve as potential markers of time to remission in patients with granulomatosis with polyangiitis. FAU - Kikuchi, Ryosuke AU - Kikuchi R AUID- ORCID: 0000-0002-9403-4302 AD - Department of Medical Technique, Nagoya University Hospital, Nagoya, Japan. FAU - Tsuboi, Naotake AU - Tsuboi N AD - Department of Nephrology, School of Medicine, Fujita Health University, Nagoya, Japan. FAU - Sada, Ken-Ei AU - Sada KE AD - Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. AD - Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan. FAU - Nakatochi, Masahiro AU - Nakatochi M AD - Department of Integrated Health Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Yokoe, Yuki AU - Yokoe Y AD - Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Suzuki, Atsuo AU - Suzuki A AD - Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Maruyama, Shoichi AU - Maruyama S AD - Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Murohara, Toyoaki AU - Murohara T AD - Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Matsushita, Tadashi AU - Matsushita T AD - Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Japan. AD - Department of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan. CN - Research Committee of Intractable Vasculitis Syndrome and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan FAU - Amano, Koichi AU - Amano K AD - Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan. FAU - Atsumi, Tatsuya AU - Atsumi T AD - Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Hokkaido, Japan. FAU - Takasaki, Yoshinari AU - Takasaki Y AD - Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan. FAU - Ito, Satoshi AU - Ito S AD - Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan. FAU - Hasegawa, Hitoshi AU - Hasegawa H AD - Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan. FAU - Dobashi, Hiroaki AU - Dobashi H AD - Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan. FAU - Ito, Takafumi AU - Ito T AD - Division of Nephrology, Shimane University, Faculty of Medicine, Shimane, Japan. FAU - Makino, Hirofumi AU - Makino H AD - Okayama University, Okayama, Japan. FAU - Matsuo, Seiichi AU - Matsuo S AD - Nagoya University, Nagoya, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20201122 PL - England TA - Ann Clin Biochem JT - Annals of clinical biochemistry JID - 0324055 RN - 0 (Biomarkers) RN - 0 (Glucocorticoids) RN - 0 (Immunosuppressive Agents) RN - 0 (VEGFA protein, human) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM MH - Aged MH - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/blood MH - Biomarkers/blood MH - Churg-Strauss Syndrome/blood MH - Cohort Studies MH - Female MH - Glucocorticoids/therapeutic use MH - Granulomatosis with Polyangiitis/*blood/*therapy MH - Humans MH - Immunosuppressive Agents/therapeutic use MH - Japan MH - Male MH - Microscopic Polyangiitis/blood MH - Middle Aged MH - Prospective Studies MH - Remission Induction MH - Vascular Endothelial Growth Factor A/*blood OTO - NOTNLM OT - Antineutrophil cytoplasmic antibody-associated vasculitis OT - rapidly progressive glomerulonephritis OT - therapeutic efficacy OT - vascular endothelial growth factor-A OT - vascular endothelial growth factor-A165b EDAT- 2020/10/22 06:00 MHDA- 2021/07/07 06:00 CRDT- 2020/10/21 05:36 PHST- 2020/10/22 06:00 [pubmed] PHST- 2021/07/07 06:00 [medline] PHST- 2020/10/21 05:36 [entrez] AID - 10.1177/0004563220968371 [doi] PST - ppublish SO - Ann Clin Biochem. 2021 Mar;58(2):86-94. doi: 10.1177/0004563220968371. Epub 2020 Nov 22.